Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
暂无分享,去创建一个
G. Stone | W. O’Neill | R. Wilensky | J. Tumlin | P. McCullough | G. Schaer | H. Madyoon | M. Stevens | P. Murray | N. Lepor | A. Chu | Andrew Wang | A. Chu
[1] S. Sdringola,et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[2] Sven-Göran Fransson,et al. Nephrotoxic effects in high-risk patients undergoing angiography. , 2003, The New England journal of medicine.
[3] Chi‐Hang Lee,et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2003, JAMA.
[4] A. Agrawal,et al. A Randomized Prospective Trial to Assess the Role of Saline Hydration on the Development of Contrast Nephrotoxicity , 2003, Nephron Clinical Practice.
[5] S. Fishbane,et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. , 2002, Kidney international.
[6] S. Allaqaband,et al. Prospective randomized study of N‐acetylcysteine, fenoldopam, and saline for prevention of radiocontrast‐induced nephropathy , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[7] William W O'Neill,et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. , 2002, Journal of interventional cardiology.
[8] I. Hizoh,et al. Radiocontrast-Induced Renal Tubular Cell Apoptosis: Hypertonic Versus Oxidative Stress , 2002, Investigative radiology.
[9] Kirk N. Garratt,et al. Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention , 2002, Circulation.
[10] J. Tumlin,et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. , 2002, American heart journal.
[11] Samin K. Sharma,et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. , 2002, The American journal of cardiology.
[12] P. McCullough,et al. Prediction and prevention of contrast nephropathy. , 2001, Journal of interventional cardiology.
[13] H. Madyoon. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. , 2001, Reviews in cardiovascular medicine.
[14] R. Ramadan,et al. Effects of A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic responses to endothelin-1. , 2000, Journal of cardiovascular pharmacology.
[15] G. Dangas,et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. , 2000, Journal of the American College of Cardiology.
[16] W Zidek,et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.
[17] M. Rudnick,et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. , 2000, Kidney international.
[18] R. Luther,et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. , 1999, Critical care medicine.
[19] G. Bakris,et al. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. , 1999, Kidney international.
[20] M. Leon,et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. , 1999, The American journal of cardiology.
[21] G. Taylor,et al. Oxygen free radicals and contrast nephropathy. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] M. Epstein,et al. Potential of dopamine A-1 agonists in the management of acute renal failure. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] E. Bates,et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] W. O’Neill,et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. , 1997, The American journal of medicine.
[25] E C Lasser,et al. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. , 1997, Radiology.
[26] R. Felder,et al. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. , 1997, Hypertension.
[27] G. Chertow,et al. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. , 1996, The American journal of medicine.
[28] C. Viscoli,et al. The effect of acute renal failure on mortality. A cohort analysis. , 1996, JAMA.
[29] P. Liss,et al. Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. , 1996, Kidney international.
[30] J. D'Elia,et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. , 1994, The New England journal of medicine.
[31] V. Bernhard,et al. Contrast-Induced Nephrotoxicity: The Effects of Vasodilator Therapy , 1993 .
[32] W. White,et al. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. , 1993, The American journal of medicine.
[33] V. Bernhard,et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. , 1992, The Journal of surgical research.
[34] R. S. Jaffe,et al. Cardiovascular Function During Induced Hypotension by Fenoldopam or Sodium Nitroprusside in Anesthetized Dogs , 1992, Anesthesia and analgesia.
[35] G. Deray,et al. Renal vasoconstriction after low and high osmolar contrast agents in ischemic and non ischemic canine kidney. , 1991, Clinical nephrology.
[36] A. S. Berns,et al. Nephrotoxicity of contrast media. , 1989, Kidney international.
[37] P. Parfrey,et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. , 1989, The New England journal of medicine.
[38] F. Douglas,et al. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. , 1987, Circulation.
[39] J. Cohen,et al. Hospital-acquired renal insufficiency: a prospective study. , 1983, The American journal of medicine.
[40] R. Neiberger,et al. Effects of dopamine on canine intrarenal blood flow distribution during hemorrhage. , 1979, Kidney international.
[41] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.